

Niraj Shenoy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8173999/publications.pdf>

Version: 2024-02-01

21
papers

847
citations

759233

12
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

1691
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. <i>Kidney International</i> , 2021, 99, 75-85.	5.2	22
2	Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	30
3	Aggressive myoepithelial carcinoma with EWSR1-POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy. <i>Cancer</i> , 2020, 126, 5198-5201.	4.1	7
4	HIF1 α is not a target of 14q deletion in clear cell renal cancer. <i>Scientific Reports</i> , 2020, 10, 17642.	3.3	10
5	Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting?. <i>BMC Medicine</i> , 2020, 18, 260.	5.5	88
6	High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1666-1677.	7.1	91
7	Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1595309.	0.7	6
8	Professional ethics in academia: defining the categories of behavior spectrum in matters of unethical conduct. <i>International Journal of Ethics Education</i> , 2019, 4, 193-194.	0.9	1
9	Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 1612-1625.	8.2	64
10	Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. <i>Cancer Cell</i> , 2018, 34, 700-706.	16.8	154
11	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1117-e1122.	1.9	1
12	Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. <i>Laboratory Investigation</i> , 2017, 97, 494-497.	3.7	24
13	Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin. <i>Practical Neurology</i> , 2015, 15, 289-292.	1.1	5
14	Is ADRM1 a Good Target for Cancer Therapy?. <i>Acta Haematologica</i> , 2015, 134, 86-87.	1.4	2
15	Role of DNA methylation in renal cell carcinoma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 88.	17.0	76
16	The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies. <i>Journal of Cancer Therapy</i> , 2015, 06, 511-521.	0.4	4
17	Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival. <i>Clinical Cancer Research</i> , 2014, 20, 4349-4360.	7.0	60
18	Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. <i>Blood</i> , 2014, 124, 873-881.	1.4	100

#	ARTICLE	IF	CITATIONS
19	Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1999-2003.	1.3	28
20	Alterations in the ribosomal machinery in cancer and hematologic disorders. <i>Journal of Hematology and Oncology</i> , 2012, 5, 32.	17.0	68
21	Protocol Modification To Determine The Cytotoxic Potential Of Drugs Using Cell Viability Assays That Rely On The Reducing Property Of Viable Cells. <i>Protocol Exchange</i> , 0, , .	0.3	3